To conclude, PTTG1 and RAC2 are critical regulators of cancer progression and promising targets in anticancer therapy due to their roles in EMT, signaling pathways like TGF-β, PI3K/AKT, and NF-κB, as well as their influence on immune evasion and therapy resistance. The gene discussed is RAC2; the disease is cancer.